Kenvue Inc. (NYSE:KVUE) Stock Holdings Reduced by Novare Capital Management LLC

Novare Capital Management LLC lowered its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 3.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 476,819 shares of the company's stock after selling 15,151 shares during the period. Novare Capital Management LLC's holdings in Kenvue were worth $11,434,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SRS Capital Advisors Inc. lifted its position in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after buying an additional 571 shares during the last quarter. Continuum Advisory LLC lifted its position in shares of Kenvue by 2,071.1% during the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock worth $47,000 after purchasing an additional 1,864 shares during the last quarter. Clarity Asset Management Inc. acquired a new position in shares of Kenvue during the 4th quarter worth about $45,000. SBI Securities Co. Ltd. acquired a new position in shares of Kenvue during the 4th quarter worth about $46,000. Finally, Rossby Financial LCC acquired a new position in shares of Kenvue during the 1st quarter worth about $52,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective for the company. Barclays boosted their price objective on Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Monday, May 12th. Redburn Atlantic assumed coverage on Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective for the company. Citigroup reissued a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Finally, UBS Group boosted their price objective on Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $25.33.

Kenvue Trading Up 0.6%

KVUE stock opened at $21.02 on Friday. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $25.17. The firm has a market cap of $40.32 billion, a P/E ratio of 38.21, a P/E/G ratio of 3.27 and a beta of 0.83. The business's 50 day moving average is $22.61 and its 200-day moving average is $22.31. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. During the same period in the prior year, the company posted $0.28 EPS. The company's revenue was down 3.9% compared to the same quarter last year. Equities analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.90%. Kenvue's dividend payout ratio is currently 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.